Dergiler / Turkish Journal of Gastroenterology / 2018 / Cilt: 29 - Sayı: 3

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Sayfa
259–269
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency.
📊
Temel Bulgular & Veri:This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency.
💡
Sonuç & Katkı:To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

🔖

Bu Makaleye Atıf Yap

AYGEN, B., DEMİR, A. M., GÜMÜŞ, M., KARABAY, O., KAYMAKOĞLU, S., KÖKSAL, A. Ş., KÖKSAL, İ., ÖRMECİ, N., TABAK, Ö. F. (2018). Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 3, 259–269. https://ajindex.com/articles/410058

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Uslu Tutar N, Ozgul E, Oguz D, Cakir B, Tarhan NÇ, Coskun M. An uncommon cause of acute abdomen-epiploic appendagitis: CT findings. Turk J Gastroenterol 2007; 18: 107-10
  2. Leclercq P, Dorthu L. Epiploic appendagitis. CMAJ: Canadian Med-ical Association Journal 2010; 182: 939. [CrossRef] 3. Singh AK, Gervais DA, Hahn PF, Sagar P, Mueller PR, Novelline RA. Acute epiploic appendagitis and its mimics. Radiographics 2005; 25: 1521-34. [CrossRef] 4. Pogorelić Z, Stipić R, Druzijanić N, et al. Torsion of epiploic append-age mimic acute appendicitis. Coll Antropol 2011; 35: 1299-302
  3. Legome EL, Belton AL, Murray RE, Rao PM, Novelline RA. Epiplo-ic appendagitis: the emergency department presentation. J Emerg Med 2002; 22: 9-13. [CrossRef]